{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T04:56:21Z","timestamp":1791608181206,"version":"4.3.4"},"reference-count":22,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T00:00:00Z","timestamp":1753747200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000135","name":"National Institutes of Health Blueprint for Neuroscience Research","doi-asserted-by":"publisher","award":["UG1 EY026876"],"award-info":[{"award-number":["UG1 EY026876"]}],"id":[{"id":"10.13039\/100000135","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007707","name":"University of California, Davis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007707","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ophthalmologyscience.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology Science"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.xops.2025.100905","type":"journal-article","created":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T23:27:37Z","timestamp":1754436457000},"page":"100905","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Randomized Study of Intravitreal Autologous CD34+ Stem Cells in Central Retinal Vein Occlusion (Treatment of Retinal vein occlusion Using STem cells [TRUST] Report 1): Safety and Feasibility"],"prefix":"10.1016","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5911-6671","authenticated-orcid":false,"given":"Susanna S.","family":"Park","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"McCormack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dagmar","family":"Salazar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacquie S.","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marisa","family":"Salvador","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Fury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehrdad","family":"Abedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ala","family":"Moshiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"Macias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kareem","family":"Moussa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radhika","family":"Kondapaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Lindblad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasmus","family":"Hoeg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan A.","family":"Nolta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xops.2025.100905_bib1","first-page":"133","article-title":"The epidemiology of retinal vein occlusion: the beaver dame eye study","volume":"98","author":"Klein","year":"2000","journal-title":"Trans Am Ophthalmol Soc"},{"key":"10.1016\/j.xops.2025.100905_bib2","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.ophtha.2009.07.017","article-title":"The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia","volume":"117","author":"Rogers","year":"2010","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xops.2025.100905_bib3","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1001\/archopht.1997.01100150488006","article-title":"Natural history and clinical management of central retinal vein occlusion. The central retinal vein occlusion group","volume":"115","year":"1997","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.xops.2025.100905_bib4","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/j.ophtha.2010.01.060","article-title":"Natural history of central retinal vein occlusion: an evidence-based systematic review","volume":"117","author":"McIntosh","year":"2010","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xops.2025.100905_bib5","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1001\/archophthalmol.2009.234","article-title":"SCORE study report 5. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion","volume":"127","year":"2009","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.xops.2025.100905_bib6","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.ophtha.2010.02.022","article-title":"Ranibizumab for macular edema following central retinal vein occlusion. Six-month prmary end point results of a phase III study","volume":"117","author":"Brown","year":"2010","journal-title":"Ophthlamology"},{"key":"10.1016\/j.xops.2025.100905_bib7","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.preteyeres.2016.10.002","article-title":"Advances in bone marrow stem cell therapy for retinal dysfunction","volume":"56","author":"Park","year":"2017","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.xops.2025.100905_bib8","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1167\/iovs.14-15415","article-title":"Intravitreal autologous bone marrow-derived CD34+ cells for ischemic and degenerative retinal disorders: preliminary phase 1 clinical trials findings","volume":"56","author":"Park","year":"2014","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.xops.2025.100905_bib9","doi-asserted-by":"crossref","first-page":"4125","DOI":"10.1167\/iovs.16-19252","article-title":"Intravitreal administration of human bone marrow CD34+ stem cells in a murine model of retinal degeneration","volume":"57","author":"Moisseiev","year":"2016","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.xops.2025.100905_bib10","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.21037\/atm-20-4662","article-title":"Subretinal versus intravitreal administration of human bone marrow CD34+ stem cells in a rat model of inherited retinal degeneration","volume":"9","author":"Park","year":"2021","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.xops.2025.100905_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.exer.2019.107865","article-title":"Intravitreal injection of human CD34+ bone marrow stem cells in a murine model of diabetic retinopathy","volume":"190","author":"Yazdanyar","year":"2020","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.xops.2025.100905_bib12","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1126\/science.275.5302.964","article-title":"Isolation of putative progenitor endothelial cells for angiogenesis","volume":"275","author":"Asahara","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.xops.2025.100905_bib13","doi-asserted-by":"crossref","first-page":"960","DOI":"10.2337\/db06-1254","article-title":"Ischemic vascular damage can be repaired by healthy, but not diabetic, endothelial progenitor cells","volume":"56","author":"Caballero","year":"2007","journal-title":"Diabetes"},{"key":"10.1016\/j.xops.2025.100905_bib14","first-page":"474","article-title":"CD34 positive stem cells in the treatment of heart and vascular disease in human beings","volume":"38","author":"Mackie","year":"2011","journal-title":"Tex Heart Inst J"},{"key":"10.1016\/j.xops.2025.100905_bib15","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1161\/CIRCRESAHA.115.308165","article-title":"PreSERVE-AMI: a randomized, double-blind, placebo-controlled clinical trial of intracoronary administration of autologous CD34+ cells in patients with left ventricular dysfunction post STEMI","volume":"120","author":"Quyyumi","year":"2016","journal-title":"Circ Res"},{"key":"10.1016\/j.xops.2025.100905_bib16","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1167\/iovs.11-8833","article-title":"Long-term effects of intravitreal injection of GMP-grade bone marrow derived CD34+ cells in NOD-SCID mice with acute ischemia-reperfusion injury","volume":"53","author":"Park","year":"2012","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.xops.2025.100905_bib17","article-title":"Phase I study of intravitreal injection of autologous CD34+ stem cells from bone marrow in eyes with vision loss from retinitis pigmentosa","volume":"5","author":"Park","year":"2024","journal-title":"Ophthalmol Sci"},{"key":"10.1016\/j.xops.2025.100905_bib18","doi-asserted-by":"crossref","first-page":"58","DOI":"10.4103\/2008-322X.200164","article-title":"Intravitreal injection of bone marrow mesenchymal stem cells in patients with advanced retinitis pigmentosa; a safety study","volume":"12","author":"Satarian","year":"2017","journal-title":"J Ophthalmic Vis Res"},{"key":"10.1016\/j.xops.2025.100905_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2019.100779","article-title":"Retinal stem cell transplantation\u2014balancing safety and potential","volume":"75","author":"Singh","year":"2020","journal-title":"Prog Ret Eye Res"},{"key":"10.1016\/j.xops.2025.100905_bib20","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1001\/jamaophthalmol.2016.0803","article-title":"Complication of autologous stem cell transplantation in retinitis pigmentosa","volume":"134","author":"Boudreault","year":"2016","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.xops.2025.100905_bib21","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1056\/NEJMoa1609583","article-title":"Vision loss after intravitreal injection of autologous \u201cStem Cells\u201d for AMD","volume":"376","author":"Kuriyan","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.xops.2025.100905_bib22","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1097\/ICB.0000000000000327","article-title":"Epiretinal membrane formation after intravitreal autologous stem cell transplantation in a retinitis pigmentosa patient","volume":"11","author":"Kim","year":"2017","journal-title":"Retin Cases Brief Rep"}],"updated-by":[{"DOI":"10.1016\/j.xops.2025.101019","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000}},{"DOI":"10.1016\/j.xops.2025.101019","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000}}],"container-title":["Ophthalmology Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666914525002039?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666914525002039?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T21:44:26Z","timestamp":1772919866000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666914525002039"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S2666914525002039"],"URL":"https:\/\/doi.org\/10.1016\/j.xops.2025.100905","relation":{},"ISSN":["2666-9145"],"issn-type":[{"value":"2666-9145","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Randomized Study of Intravitreal Autologous CD34+ Stem Cells in Central Retinal Vein Occlusion (Treatment of Retinal vein occlusion Using STem cells [TRUST] Report 1): Safety and Feasibility","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xops.2025.100905","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 by the American Academy of Ophthalmology.","name":"copyright","label":"Copyright"}],"article-number":"100905"}}